Replimune Group (NASDAQ:REPL) Posts Quarterly Earnings Results, Beats Estimates By $0.24 EPS

Replimune Group (NASDAQ:REPL) issued its quarterly earnings data on Wednesday. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.24, FiscalAI reports.

Here are the key takeaways from Replimune Group’s conference call:

• TUDRIQEV’s launch is showing early traction: More than 70% of the initial 200 target accounts have been engaged, approximately 20 have added the drug to formulary, and more than 15 institutions had written prescriptions within the first 20 business days.
• Replimune reported strong physician interest across academic, community, oncology, and interventional radiology settings, with both superficial and image-guided injections already being used. Management expects the number of accounts initiating patients could potentially double by year-end.
• Coverage appears to be broad and favorable: TUDRIQEV has a Category 2A NCCN recommendation, Medicare coverage, and commercial payer policies covering its label—including retreatment in appropriate cases—with a permanent J-code expected by April 2027.
• The company reported no product revenue in the fiscal second quarter because commercial shipments began in October; it will report initial product revenue in the fiscal third quarter but is not providing revenue guidance. TUDRIQEV’s list price is $450,000 per treatment course before discounts, with revenue recognized over multiple quarters in some cases.
• Replimune ended the quarter with $307.8 million in cash, including $141 million from an August offering, and expects funding to support operations for more than 12 months while investing in the launch, IGNYTE-3, and the REVEAL uveal melanoma study.

Replimune Group Stock Up 12.6%

REPL traded up $1.65 on Wednesday, hitting $14.70. 2,424,706 shares of the company were exchanged, compared to its average volume of 4,305,073. Replimune Group has a twelve month low of $1.50 and a twelve month high of $16.33. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -4.67 and a beta of 0.93. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00. The firm has a 50-day moving average price of $13.45 and a two-hundred day moving average price of $9.21.

Analyst Upgrades and Downgrades

REPL has been the subject of several research reports. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price target on the stock in a research note on Tuesday, June 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. Weiss Ratings cut Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Finally, Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $11.00 to $17.00 in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $12.00.

Insider Buying and Selling

In other Replimune Group news, insider Konstantinos Xynos sold 11,447 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,467.59. Following the completion of the transaction, the insider owned 224,215 shares in the company, valued at $2,908,068.55. The trade was a 4.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the completion of the transaction, the chief executive officer owned 708,151 shares in the company, valued at approximately $9,184,718.47. The trade was a 5.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 79,124 shares of company stock worth $1,038,364 in the last quarter. Company insiders own 5.40% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.